OMNIMED EQUITY PARTNERS, L.P.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$14M
Investors
78
Min Invest
$100,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
OMNIMED EQUITY PARTNERS, L.P. is a Texas limited partnership that first filed a Form D on March 14, 2018 and most recently amended it on August 5, 2022, describing itself as a private equity fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(1) and covers equity and pooled investment fund interests. OMNIMED EQUITY PARTNERS, L.P. reported $14,055,955 sold from 78 investors in an offering of indefinite size as of the Form D filed August 5, 2022. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $100,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 8383 Preston Center Plaza Dr., Suite 360, Dallas, TX 75225.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
lapsed
Fund family Part of the Omnimed Equity Partners family: 4 vehicles across 2 generations · adviser of record Omnimed Capital LLC · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 326628 · exempt reporting adviser · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: Weaver And Tidwell, L.L.P. · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
GREGORY WOOD
Director · DALLAS, TX
MANAGING DIRECTOR OF THE GENERAL PARTNER OF THE ISSUER
GARY WOOD
Director · DALLAS, TX
MANAGING DIRECTOR OF THE GENERAL PARTNER OF THE ISSUER
OMNIMED CAPITAL, LLC
Promoter · DALLAS, TX
GENERAL PARTNER OF THE ISSUER
Questions About OMNIMED EQUITY PARTNERS, L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is OMNIMED EQUITY PARTNERS, L.P.?
OMNIMED EQUITY PARTNERS, L.P. is a Texas limited partnership that filed a Form D with the SEC on August 5, 2022 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of equity and pooled investment fund interests.
Is OMNIMED EQUITY PARTNERS, L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. OMNIMED EQUITY PARTNERS, L.P. filed a Form D with the SEC on August 5, 2022 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $14,055,955 sold to 78 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is OMNIMED EQUITY PARTNERS, L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that OMNIMED EQUITY PARTNERS, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has OMNIMED EQUITY PARTNERS, L.P. raised?
OMNIMED EQUITY PARTNERS, L.P. reported $14,055,955 sold from 78 investors in an offering of indefinite size as of the Form D filed August 5, 2022.
Who can invest in OMNIMED EQUITY PARTNERS, L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $100,000.
What is the minimum investment in OMNIMED EQUITY PARTNERS, L.P.?
The Form D lists $100,000 as the minimum investment accepted from any outside investor as of August 5, 2022. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling OMNIMED EQUITY PARTNERS, L.P. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind OMNIMED EQUITY PARTNERS, L.P.?
The Form D lists 3 related persons: GREGORY WOOD, director (MANAGING DIRECTOR OF THE GENERAL PARTNER OF THE ISSUER); GARY WOOD, director (MANAGING DIRECTOR OF THE GENERAL PARTNER OF THE ISSUER); OMNIMED CAPITAL, LLC, promoter (GENERAL PARTNER OF THE ISSUER). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is OMNIMED EQUITY PARTNERS, L.P. located?
The issuer's address on its SEC filings is 8383 Preston Center Plaza Dr., Suite 360, Dallas, TX 75225. Its phone number of record is 972.701.5412. It is organized under the laws of Texas.
How long is the OMNIMED EQUITY PARTNERS, L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 5 amendments are on record for this CIK.
How large is OMNIMED EQUITY PARTNERS, L.P.?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.